# Ronnie Shapira‐Frommer

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ronnie-shapira-frommer/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,377 |
| Field | Cytokine Signaling Pathways and Interactions |
| h-index | 48 |
| i10-index | 100 |
| Last Known Institution | Sheba Medical Center |
| OpenAlex ID | https://openalex.org/A5058238015 |
| ORCID iD | https://orcid.org/0000-0001-6170-080X |
| Works | 290 |

## Researcher papers

- [Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer](https://scholariq.org/papers/olaparib-maintenance-therapy-in-platinum-sensitive-relapsed-ovarian-cancer/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation](https://scholariq.org/papers/olaparib-monotherapy-in-patients-with-advanced-cancer-and-a-germline-i-brca1-2-i/)
- [Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients](https://scholariq.org/papers/fecal-microbiota-transplant-promotes-response-in-immunotherapy-refractory/)
- [Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer](https://scholariq.org/papers/pembrolizumab-for-persistent-recurrent-or-metastatic-cervical-cancer/)
- [ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease](https://scholariq.org/papers/esgo-esmo-esp-consensus-conference-recommendations-on-ovarian-cancer-pathology/)
- [Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2](https://scholariq.org/papers/antitumor-activity-and-safety-of-the-parp-inhibitor-rucaparib-in-patients-with/)
- [A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors](https://scholariq.org/papers/a-phase-i-ii-study-of-the-oral-parp-inhibitor-rucaparib-in-patients-with/)

## Researcher topics

- [Cytokine Signaling Pathways and Interactions](https://scholariq.org/topics/cytokine-signaling-pathways-and-interactions/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Myeloproliferative Neoplasms: Diagnosis and Treatment](https://scholariq.org/topics/myeloproliferative-neoplasms-diagnosis-and-treatment/)

## Researcher university

- [Sheba Medical Center](https://scholariq.org/institutions/sheba-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.